Healthcare Industry News: Dermal Filler
News Release - June 7, 2006
FzioMed Announces Launch of UK Subsidiary & Appoints Amanda Cameron as UK General ManagerSAN LUIS OBISPO, Calif.--(HSMN NewsFeed)--June 7, 2006--FzioMed, Inc. announced today the establishment of its operating subsidiary in the United Kingdom and appointment of Amanda Cameron to the position of UK General Manager. The new company, FzioMed Limited UK, will be headquartered in London and will lead the company's sales expansion into the European aesthetic surgery market.
FzioMed, Inc. is headquartered in San Luis Obispo, California with a secondary manufacturing facility in The Netherlands. Under Amanda's leadership, the new subsidiary will be responsible for launching the company's Laresse(TM) Dermal Filler product in the UK in June 2006 and will expand direct sales of the product throughout Europe later this year.
"These two initiatives give FzioMed a strong start in our expansion into the European aesthetics and dermatology markets," said John Krelle, FzioMed, Inc. President and Chief Operating Officer. "We are very pleased to welcome Amanda to the FzioMed team and to establish a dedicated business entity for the successful launch of our Laresse product line."
Amanda has twenty years of experience in the medical device and pharmaceutical industry with specialization in aesthetics and dermatology. Amanda most recently held the position of Head of Dermatology at Sanofi Aventis in the U.K. Her background includes management positions in leading medical corporations, including Vice President International for Collagen Aesthetics, International Marketing Director and Business Manager for Collagen UK Ltd, and Training Manager for Glaxo Laboratories. Amanda holds a Masters in Business Administration (MBA) and has over ten years of clinical nursing experience.
Laresse Dermal Filler is a completely new development in Dermal Fillers based on FzioMed's patented science. The smooth, easy-flowing gel is composed of pure, absorbable medical polymers. Laresse is long lasting but non-permanent and is the first filler without many of the drawbacks of hyaluronic acid and collagen fillers. Laresse is not manufactured from either bacterial or animal sources and it is not chemically cross-linked.
FzioMed is a privately held medical company developing and commercializing absorbable biomaterials based on the company's patented Oxiplex technology. Oxiplex is an innovative absorbable polymer with uses in a variety of specialties including orthopedics, spine, gynecology, general surgery and aesthetic surgery. FzioMed products include Oxiplex/SP, the leading adhesion barrier for spine surgery currently marketed outside of the United States, Oxiplex/AP adhesion barrier for gynecologic and general surgery, and Laresse cosmetic Dermal Filler. FzioMed products are for investigational use only in the U.S.
FzioMed®, Oxiplex® and Laresse(TM) are trademarks of FzioMed, Inc.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.